Clinical Trial News Archive - June 2022
June 1, 2022
- Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
- FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation for Hemophilia A
- Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
June 3, 2022
June 5, 2022
- Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory Multiple Myeloma
- Updated Data for Janssen’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
June 6, 2022
June 7, 2022
- FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
- Merck and Ridgeback Announce New Data For Investigational Lagevrio (molnupiravir) From Phase 3 MOVe-OUT Study
- Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
June 8, 2022
- Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial
- First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
June 9, 2022
June 10, 2022
- AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
- GSK Announces Positive Pivotal Phase III Data for its Respiratory Syncytial Virus (RSV) Vaccine Candidate for Older Adults
- CyanVac Announces Data from Preclinical Studies of Intranasal PIV5-based COVID-19 Vaccine Candidate CVXGA1
- ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
June 11, 2022
- Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
June 13, 2022
- Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
- TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
June 14, 2022
- Pfizer Reports Additional Data on Paxlovid Supporting Upcoming New Drug Application Submission to U.S. FDA
- Clincierge Releases Study on Patient Experience in Clinical Trials
June 15, 2022
- Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
- Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine
June 16, 2022
June 17, 2022
- Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
- Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
- Dasynoc Granted Orphan Drug Designation in the US for the Treatment of Chronic Myeloid Leukemia
June 20, 2022
June 21, 2022
- Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
- Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
- Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
June 22, 2022
- First Subject Dosed in Phase 1b Clinical Trial of Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
- Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of Nemolizumab in Patients with Prurigo Nodularis
- Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
June 23, 2022
- Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
- ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilisation from Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
- Researchers Find That a Japanese Medicinal Mushroom Extract Can Help the Body Clear Persistent HPV Infections
June 24, 2022
- Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
- Sanofi-GSK First to Report a Successful Efficacy Study Against Omicron with COVID-19 Beta-Containing Vaccine
- Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model
June 25, 2022
June 27, 2022
June 28, 2022
- Basilea Announces Positive Results of Phase 3 ERADICATE Study with Ceftobiprole in Staphylococcus Aureus Bacteremia (SAB)
- Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
- NIH Scientists Identify New Brain Mechanism Involved in Impulsive Cocaine-Seeking in Rats
- Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
- Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
June 29, 2022
- Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
- DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors
- Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856
June 30, 2022
Clinical trial results archive
- 2025
- January, February, March, April, May, June
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.